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Summary L-[methyl-"1C]methionine ("IC-methionine) uptake of seven primary breast cancers, four soft tissue
metastases of breast cancer, and three other breast lesions was studied by positron emission tomography
(PET). "C-methionine accumulation was assessed by calculating the standardised uptake value (SUV). The
mean SUV for breast cancer was 8.5±3.3 (s.d.), while the maximal uptake in the liver was 12.4±1.6, in the
bone marrow 5.8 ±0.7, and in the myocardium 3.4±0.6. All eight malignant tumours larger than 30mm in
diameter accumulated clearly "C-methionine, whereas none of the three smaller cancers (from 12 to 15 mm in
diameter) were visualised. Strong uptake of "C-methionine was associated with a large S-phase fraction (SPF)
measured with flow cytometry (r = 0.77, P = 0.01), and the non-visualised cancers had all a small SPF
(<5.5%). One benign tumour (an abscess) accumulated slightly IIC-methionine. The results indicate that both
primary and metastatic breast cancer can be effectively imaged with "IC-methionine by PET, and that the
accumulation of "C-methionine may correlate with the proliferation rate of breast carcinoma.
Methionine metabolism is altered in malignant tissue (Hoff-
man, 1984). Physiologically, methionine is needed for protein
synthesis. It is also converted to S-adenosylmethionine, which
is the predominant biological methyl group donor in several
biochemical reactions in vivo. Furthermore, it is essential as a
precursor in polyamine synthesis pathways, and contributes
to the trans-sulfuration pathway. In addition to increased
protein synthesis rate and increased need for polyamines, the
transmethylation rate of cancer cells is high (Stern & Hoff-
man, 1984).
L-[methyl-[lC]methionine ("C-methionine) is a useful amino
acid for positron emission tomography (PET) studies on
tumours. The uptake of "IC-methionine is increased in glio-
mas and lung cancer, and the accumulation may be related to
the histological grade of cancer (Derlon et al., 1989; Fujiwara
et al., 1989).
In the present study, breast cancer and its soft tissue
metastases were investigated with "IC-methionine by PET to
find out if "IC-methionine can be used to image breast
cancer. Since "C-methionine uptake is associated with the
metabolism of cancer cells, the accumulation of "'C-methio-
nine in the breast tumours was studied by PET to assess
whether "C-methionine and PET is a useful method to assess
the proliferation rate of breast cancer.
Patients and methods
Patients
Fourteen patients underwent evaluation for a breast mass or
recurrent breast cancer participated in the study and gave
written informed consent. Seven patients turned out to have
primary breast cancer, one had recurrent breast cancer in the
thoracic wall, and three had metastatic breast cancer in a
lymph node of the neck or the ipsilateral axilla (Table I).
Histologically the tumours consisted of infiltrating ductal
(n = 9) or lobular (n = 2) carcinoma. Two patients had a
palpable tumour which turned out to be an abscess and
mastitis, respectively. One patient had a palpable mass,
benign by mammography, with a diameter of 3 cm in her left
breast. The histology of the mass is not known, because the
patient refused surgery, but the mass has remained unchang-
ed during follow-up for 1 year. Tumour size was retrieved
from the surgical reports.
Twelve women received no therapy for cancer prior to the
PET-study. Patient no. 11 (Table I) received one cycle of
combination chemotherapy consisting of cyclophosphamid,
methotrexate and 5-fluorouracil (CMF) 6 weeks before the
study. Patient no. 10 was receiving adjuvant CMF because of
cancer in her left breast, when a new fast growing tumour
was detected in the contralateral breast. The last CMF
course was given 5 weeks before the PET study. The tumour
of the right breast was imaged; it turned out to be breast
cancer.
The study was approved by the Ethical Committee of
Turku University Central Hospital.
PET imaging and analysis
"C-methionine was synthesised at the Turku Medical Cyclo-
tron Laboratory as described elsewhere (Langstrom et al.,
1987; Nagren et al., 1990). The radiochemical purity of "C-
methionine was over 91%.
All patients had a light protein poor-breakfast 3 to 4 h
before the scanning. Transmission scanning was performed
with-a removable ring source containing ssGe for attenuation
correction immediately before the emission scan to a total
count of 15-30 x 106 per plane. For patient no. 4 attenua-
tion correction was done by calculation. After a transmission
scanning, "C-methionine (85-300 MBq) was injected into a
peripheral vein of the upper extremity. Following the injec-
tion, a dynamic..scanning with 16 frames was carried out for
40 min. The - last 4 frames were 5 min each, except for
patients I and 6, who, for logistic reasons, had only a 30 min
dynamic scan 20 to 50 min after the injection. An ECAT
Scanner type 931/08-12 was used for PET imaging. The
device acquires 15 contiguous slices simultaneously with a
slice thickness of 6.7 mm; the full width of the halfmaximum
is 6.1 mm transaxially in the centre of the field of view
(Spinks et al., 1988).
The regions of interest (ROI) were drawn on the hot spots
in the tumour so that the standard deviation in the ROI was
less than 15% in the last frames. Several ROIs with high
accumulation were selected from the total tumour tissue,
because "C-methionine accumulation was clearly heterogen-
ous in several cases (Figure 1). The size of the ROI selected
was always smaller than the total tumour area per plane.
ROIs were also drawn on the contralateral normal breast
tissue.
Standardised uptakes values (SUV) were calculated for
each patient as follows:
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SUV= Radioactivity Concentration in ROI [Bg mm-3]
Injected Dose [BqJ / Weight of the Patient [g]
where Radioactivity Concentration in ROI is the maximum
radioactivity concentration in the tumour measured by PET,
corrected for calibration and decay. Since the uptake of
"C-methionine in breast cancer was rapid and the time
activity curve of '"C-methionine achieved a plateau 10-15
min after the injection, the ROI with a maximum average
count at 35-40 min after injection was selected to represent
the "C-methionine uptake in the tumour. The dose is the
injected tracer dose. The PET data were analysed blindly
without knowledge on the histological or flow cytometric
results.
Flow cytometry
The fraction of cells in the S-phase (S-phase fraction, SPF)
was determined by DNA flow cytometry from deparaffinised
tissue sections. The preparation of a single cell suspension
was done according to a slight modification of the method
described by Hedley et al. (1983). DNA was stained with
propidium iodide, and flow cytometry was done with a
FACScan flow cytometer (Becton-Dickinson Immunocyto-
metry Systems, Mountain View, CA) as described elsewhere
(Joensuu & Klemi, 1988). SPF was calculated using the
rectangular method (Camplejohn et al., 1989). SPF was
determined blindly without knowledge on the imaging
results. The time interval between the biopsy and the PET
scanning was from 2 to 4 weeks, except in case 8, where it
was 6 months.
Statistical analysis
SPF and SUV values were plotted on the x- and y-axis,
respectively, and analysed by linear regression. The correla-
tion coefficient (r) and the 95% confidence intervals were
calculated.
Results
All malignant tumours with a maximum diameter larger than
30 mm were clearly visualised with "C-methionine; the SUVs
ranged from 5.7 to 15.1 (Table I, Figures 1 and 2). Neither
the three primary cancers with the maximum diameter from
12 to 15 mm, the case ofmastitis, nor the tumour that lacked
histological verification were visualised, while an abscess with
a diameter of 25 mm accumulated weakly "C-methionine
(SUV 4.0). The axillary metastasis accumulated slightly less
"C-methionine than the primary tumour in the chest wall
(SUV 4.5 and 5.7, respectively) of patient 7 who had recur-
rent scar tumour and an axillary metastasis.
The uptake of "C-methionine in the normal breast tissue
was low (SUV 1.1 ± 0.2, mean ± s.d.), which yielded a good
contrast ratio between cancer and breast tissue (Figures 1
and 2). The accumulation of'1C-methionine was considerably
greater in some internal organs. The highest uptakes of "C-
methionine were measured in the pancreas (SUV 34.3, n = 1)
and the liver (SUV 12.4 ± 1.6, n = 7, Table I, Figure 3). The
uptake of "C-methionine in the bone marrow was also high
(SUV 5.8 ± 0.7, n = 7), except in patient 10 (SUV 2.9), who
was known to have therapy-induced bone marrow hypo-
plasia. The uptake was lower in the myocardium than in the
bone marrow, the SUVs ranged from 2.8 ± 0.5 (minimum +
s.d.) to 3.4 ± 0.6 (maximum ± s.d.). The patients included in
this study were not known to have any cardiac disease.
The accumulation of "C-methionine in the tumours cor-
related well with the size of SPF (r = 0.77 and P = 0.01,
n = 9, Figure 4, panel a). The three cancers which did not
show up on the PET-image had low SPFs ranging from 4.2
to 5.3%. The accumulation of "C-methionine correlated also
positively with tumour size (r = 0.77, P = 0.02, n = 9, Figure
4, panel b).
Discussion
Increased uptake of "C-methionine in breast cancer as com-
pared with the surrounding breast parenchyme has not been
reported earlier, but "IC-methionine has been found to be an
effective tracer in lung cancer and gliomas (Derlon et al.,
1989; Fujiwara et al., 1989). In both lung cancer and glioma
uptake of 'IC-methionine correlates with the histological
grade of cancer - a finding which is in line with the present
finding of an association between cancer proliferation rate as
measured with the SPF and "IC-methionine uptake. Cancer
proliferation rate in turn has been found to be associated
with adverse prognosis in breast cancer (Toikkanen et al.,
1989).
"C-methionine uptake was expressed by a semiquantitative
value (SUV) which has been found to be valid for tumour
PET studies (Kubota et al., 1985). A kinetic analysis where
the plasma "C-methionine level is used as the input function
appears also to be an acceptable analysis method, but the
complicated metabolism of methionine has made it difficult
to create a precise metabolic model.
An association was found not only between "IC-methionine
uptake and SPF, but also between "C-methionine uptake
and tumour size (Figure 4). Because the resolution of the
PET scanner was less than 7 mm, the correlation between
Table I Clinical, histological, DNA flow cytometry and "C-methionine accumulation data of 14 women
with breast tumour
Patient Age Tumour grade Maximum SUV SUV SUV SUV
No. (yr) Type' diameter (mm) SPF tumour liver BMb Hearf
I 50 Abscess- 25 1.9 4.0 12.5 5.5 3.1-3.4
2 47 P II 12 4.2 NA 11.6 5.0 2.4-2.6
3 61 P II 12 4.3 NA ND ND ND
4 58 P II 15 5.3 NA 15.5 6.1 ND
5 51 P III 40 8.5 5.8 ND 5.7 2.7-3.7
6 84 P II 40 9.2 7.5 ND ND ND
7 69 M III 30 10.1 5.7 11.0 ND ND
8 40 P III 55 10.8 7.0 13.2 5.1 2.4-3.0
9 63 M III 50 15.2 10.8 ND ND ND
10 50 M III 30 25.3 6.2 ND 2.9 ND
11 67 M III 100 28.5 10.2 ND ND ND
12 92 P III 80 33.0 15.1 11.7 6.5 ND
13 79 $ - 30 ND NA ND 7.0 3.6-4.1
14 37 Mastitis - 20 ND NA 11.2 ND ND
aTumour types: P = primary breast cancer; M = relapsed or mestatic tumour. bBM = bone marrow.
$ = PAD not available; see text. ND = Not defined; NA = No tumour accumulation in PET image. cMinimum and maximum values formyocardium accumulation. SPF = S-phase fraction; SUV = Standar-






Figure 1 PET "IC-methionine image of patient 12. The infiltrat-
ing ductal carcinoma with hypometabolic centre is imaged in her
lateral left breast (arrow). The uptake of "C-methionine in the
liver is clearly seen on the right side of the image. A = Anterior,
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Figure 2 PET "C-methionine image of patient 5 with infiltrating
ductal carcinoma in the lateral right breast (arrow). Some uptake
of "C-methionine can be seen in the upper parts of the heart and
in the bone marrow (BM).
D
Liver BM Heart Cancer
Figure 3 Mean SUVs with SD-bars of the accumulation of
"C-methionine in the liver (n = 7), bone marrow (BM) (n = 8),
myocardium (n = 5) and breast cancer (n = 8) at 35-40 min after
the injection.
"C-methionine uptake and tumour size or the SPF in
tumours larger than 20 mm in diameter is not affected by the
partial volume effect. The three tumours with a smaller
diameter (from 12 to 15 mm) were not visualised with "C-
methionine, which may be explained by their lower rate of
methionine metabolism and smaller proliferation rates (SPF
Tumour size (mm)
Figure 4 a, Linear regression plot of SUV of "C-methionine
uptake in breast cancer and SPF with 95% confidence areas
(r = 0.77, P = 0.01). b, Linear regression plot of SUV of "C-
methionine uptake in breast cancer and size of tumour with 95%
confidence areas (r = 0.77, P = 0.02).
less than 5%). However, the effect of spatial resolution on
the intensity of the accumulation of "C-methionine in small
tumours (i.e. tumours with a diameter <20 mm) invalidates
the assessment of the uptake rate. Tumour size does not
appear to correlate strongly with SPF in large series (Toik-
kanen et al., 1989).
The association between methionine uptake and tumour
proliferation rate may vary in different types of human
cancer. We recently studied this association in 14 non-
Hodgkin's lymphomas, but no significant association was
found (Leskinen-Kallio et al., 1991). "C-methionine uptake
in a tumour appears to be a complex process and related to
several factors, such as amino acid transport and metabolism
of both cancer and stromal cells, and tumour blood flow
(Abe et al., 1988).
"IC-methionine did not accumulate in a focus of inflamed
breast tissue, but did accumulate in an abscess. Although the
SUV of the abscess was lower than in any ofthe cancers with
visible uptake, accumulation of "C-methionine in a breast
tumour is not a conclusive sign of malignancy. There are at
present no data on the radiopharmacokinetics of "C-methio-
nine in other benign breast tumours, such as fibroadenomas.
The uptake values of "C-methionine in the pancreas and
the liver were in line with those reported by Syrota et al.
(1982). Thus, the high uptake of "C-methionine in the pan-
creas and the liver may impair the value of "C-methionine as
a tumour seeking agent in the upper abdomen. To our
knowledge, the uptake values of "C-methionine in the nor-
mal human bone marrow or the myocardium have not been
reported earlier. The decreased SUV in the bone marrow of
patient no. 10 with histologically confirmed drug-induced
marrow hypoplasia is of potential interest, and the use of
-
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"C-methionine uptake as an indicator of bone marrow func-
tion needs to be evaluated.
At its present technological stage of development, PET
scanning with "C-methionine cannot replace the quick and
inexpensive conventional methods, such as mammography or
fine needle aspiration biopsy in diagnosing breast tumours.
The value of "C-methionine-PET technique lies in its poten-
tial usefulness to assess the proliferation rate of deeply situ-
ated breast cancer tumours non-invasively. Further studies
are needed to determine whether this method has clinical
implication in assessing early metabolic treatment response of
breast cancer.
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